Entity

Time filter

Source Type

Xiamen, China

Xiamen University , colloquially known as Xia Da ". The university is one of many comprehensive universities directly administered by the Chinese Ministry of Education. In 1995 it was included in the list of the 211 Project for the state key construction; in 2000 it became one of China's higher-level universities designated for the state key construction of the 985 Project.According to University Undergraduates Teaching Assessment and Chinese Universities Evaluation Standings, the university is ranked 11th in China and has maintained the top 20 ranking in China, among which 6 subjects reach A++ level, including economics and management,fine art, law, chemistry, journalism, communication and mathematics.In addition,the school of management is accredited by EQUIS and AMBA. Wikipedia.


Gu W.-M.,Xiamen University
Astrophysical Journal | Year: 2015

Based on the no-outflow assumption, we investigate steady-state, axisymmetric, optically thin accretion flows in spherical coordinates. By comparing the vertically integrated advective cooling rate with the viscous heating rate, we find that the former is generally less than 30% of the latter, which indicates that the advective cooling itself cannot balance the viscous heating. As a consequence, for radiatively inefficient flows with low accretion rates such as M ≲ 10-3 MEdd, where MEdd is the Eddington accretion rate, the viscous heating rate will be larger than the sum of the advective cooling rate and the radiative cooling one. Thus, no thermal equilibrium can be established under the no-outflow assumption. We therefore argue that in such cases outflows ought to occur and take away more than 70% of the thermal energy generated by viscous dissipation. Similarly, for optically thick flows with extremely large accretion rates such as M ≳ 10 MEdd, outflows should also occur owing to the limited advection and the low efficiency of radiative cooling. Our results may help to understand the mechanism of outflows found in observations and numerical simulations. © 2015. The American Astronomical Society. All rights reserved. Source


The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analogue anti-HBV drug), and thus guide the patients to reasonably choose drugs.


Patent
Xiamen Innovax Biotech Co. and Xiamen University | Date: 2014-03-17

The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.


Patent
YANG SHENG TANG COMPANY Ltd and Xiamen University | Date: 2012-08-13

The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS.


Patent
Xiamen Innovax Biotech Co. and Xiamen University | Date: 2012-06-01

Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.

Discover hidden collaborations